FDA declines request for fluvoxamine to be used as COVID-19 treatment

The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.
In a 25-page memo, the FDA said there were insufficient data showing that the medication, fluvoxamine maleate, “may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization.”
The request for an emergency use authorization was based on data from the randomized placebo-controlled TOGETHER trail conducted in Brazil, which

The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.
In a 25-page memo, the FDA said there were insufficient data showing that the medication, fluvoxamine maleate, “may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization.”
The request for an emergency use authorization was based on data from the randomized placebo-controlled TOGETHER trail conducted in Brazil, which